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Laboratory measures of antigen-specific immunity are an
essential component of the vaccine discovery process. For hu-
man immunodeficiency virus type 1 (HIV-1), this process will
likely require iterative evaluations of vaccine immunogens to
choose the most promising vaccine candidates to advance into
human trials. To optimally evaluate and compare vaccine im-
munogens, we will need high-throughput assays that allow ac-
curate and reproducible measurements of immune responses.
In addition, vaccine sponsors and regulatory agencies appro-
priately require that immune assays associated with human
trials be performed in laboratories that comply with guidelines
for good laboratory practices (GLP). The rigorous process of
assay validation associated with GLP can improve the accuracy
of immune assessment assays and contribute to vaccine devel-
opment by advancing our ability to distinguish incremental
improvements in immune responses elicited by novel immuno-
gens. In this commentary, we address several of these issues
with regard to the measurement of anti-HIV-1 neutralizing
antibodies (NAbs). We recommend the use of DNA plasmids
encoding full-length functional HIV-1 envelope glycoproteins
(Env); these env clones, when transfected with an HIV-1 env-
defective molecular clone, produce well-characterized HIV-1
Env pseudovirions. Additionally, we recommend the establish-
ment of standardized panels of Env-pseudotyped viruses to
assess the potencies and breadths of NAbs elicited by vaccine
immunogens. These virus panels would form the basis for GLP
neutralization assays used to assess sera from clinical vaccine
studies, and the same virus panels could be used by investiga-
tors interested in the preclinical evaluation of vaccine immu-
nogens.
Studies of AIDS virus infection in animal models and of
HIV-1 infection in humans have shown that virus-specific
CD8 T cells and NAbs are two important immune responses
to monitor as potential correlates of effective vaccination
against HIV-1/AIDS (14, 17, 30). In particular, NAbs can con-
fer protective immunity against lentiviral infection in animal
models (7, 20, 28, 29, 31, 36). While antibodies could affect
HIV-1 transmission by mechanisms that are not yet appreci-
ated or readily measured, the ability to generate potent and
broadly cross-reactive NAbs remains a major scientific obstacle
and a high priority for HIV-1 vaccine development. Various
assays are used to measure antibodies that neutralize HIV-1
and the related simian immunodeficiency virus and simian-
human immunodeficiency virus (4, 5, 9–11, 13, 18, 22–25, 27,
33–35, 37, 41–43). These assays rely on different technologies,
but all are based on the principle of measuring reductions in
virus infectivity in cells that express the suitable fusion recep-
tors for virus entry. These assays can differ with regard to the
type of target cells, the methodology for detecting viral infec-
tion, the type of virus used, and whether single or multiple
rounds of infection are permitted (Fig. 1). While these diverse
assays can produce qualitatively similar results in terms of how
each assay rank-orders neutralization potency (6, 40), there are
likely to be substantial differences in accuracy and reproduc-
ibility and differences in the potential for the assays to be
performed on large sample sets under GLP conditions.
Recent technological advances have provided the means to
standardize several aspects of virus neutralization assays. En-
gineered cell lines expressing high levels of CD4, CCR5, and
CXCR4 can be substituted for primary human T cells (23, 32,
33, 41), thus alleviating the requirement for individual donor
cells. In addition, it is possible to utilize Env-pseudotyped
lentiviral vectors expressing any HIV-1 Env that can be cloned
into an appropriate DNA expression plasmid (3, 33, 41). The
Env is expressed in trans with an env-deficient HIV-1, and the
resulting Env-pseudotyped virions produce a single round of
infection that can be monitored by reporter genes carried in
the virus or the engineered cell line. A recent study by Binley
et al., in which over 90 Env pseudoviruses were studied with
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well-known antibody reagents, is a clear example of the utility
of this proposed assay (1). Cloning of functional env genes
from plasma viral RNA or from proviral DNA from primary
peripheral blood mononuclear cells (PBMC) or cultured
PBMC is possible. Thus, it is now feasible to consider the use
of well-characterized reference strains of HIV-1 to evaluate
the neutralizing antibody response elicited by HIV-1 vaccine
candidates. The use of appropriate positive and negative con-
trol reagents and a rigorous program of proficiency testing can
then ensure that assays performed in different laboratories
generate equivalent data.
A major obstacle for effective antibody-based immunization
against HIV-1 is viral diversity (8, 19, 38). To be effective, an
HIV-1 vaccine will likely have to generate antibodies that neu-
tralize a genetically and antigenically diverse set of viruses.
Only by employing multiple viral strains in neutralization as-
says can the breadth of the NAb response be ascertained in a
meaningful way. Currently, various HIV-1 strains are used by
different laboratories, creating a lack of uniformity that has
made it difficult to compare immunogens. Thus, there is a
pressing need to establish standard panels of HIV-1 strains for
wide distribution and use (26). The creation of standard virus
panels would facilitate proficiency testing and GLP assay val-
idation and would allow consistent data sets to be acquired that
could be used to compare new immunogens and to prioritize
the advancement of candidate vaccines. This prioritization
could occur at the preclinical stage, to decide which vaccines to
test in humans, and during phase I/II trials, to prioritize can-
didate vaccines for advanced clinical development. Standard
panels would also allow refined measurements that might re-
veal incremental improvements in immunogen design. This
would provide an increased understanding of the barriers to
effective NAb induction and identify vaccine design concepts
that deserve further development.
Standard virus panels will need to consist of a practical
number of virus strains that represent diverse neutralization
epitopes. The criteria for strain selection and related scientific
issues were discussed at a workshop sponsored by HIV Vac-
cine Trials Network and Division of AIDS, National Institutes
of Health (NIH), and attended by approximately 50 scientists
(Duke University, 6 January 2004). Further discussion took
place during meetings on laboratory standardization spon-
sored by the Global HIV/AIDS Vaccine Enterprise. There was
general agreement that there is a pressing need to compare the
NAb responses elicited by current vaccine immunogens and
that initial virus panels should be devised as soon as possible.
These panels may need to be modified in the future as new
information becomes available. For the purpose of initial cat-
egorization, it was recommended that virus panels be com-
prised mainly of contemporary virus strains that are obtained
within 3 months of sexually transmitted infection and that
these viruses be grouped by genetic subtype. Recently trans-
mitted viruses were preferred in order to avoid the potential
consequences of viral genetic and antigenic drift. Sexually
transmitted viruses from newly infected individuals were rec-
ommended because they most closely represent the viral
strains that a vaccine will need to protect against (3, 16, 21, 39,
44–46). A further rationale for grouping isolates by genetic
subtype is that over 90% of HIV-1 variants belong to genetic
subtypes A, B, C, D, E (CRF01), and A/G (CRF02) (12). In
the absence of definitive information about neutralization se-
rotypes, the use of separate virus panels corresponding to each
of these six major genetic subtypes makes intuitive sense.
Numerous additional criteria for selection of viruses were
discussed. In order not to overestimate or underestimate the
NAb response, the limited number of viruses in each panel
should exhibit a distribution of neutralization phenotypes that
is generally representative of most primary isolates; i.e., viruses
that are exceptionally neutralization sensitive or resistant
would not be included. The viruses in each panel should also
be genetically and geographically diverse and represent diverse
neutralization epitope specificities, as best as this can be de-
FIG. 1. Common types of assays used to measure neutralizing antibodies against HIV-1. Current assays differ with regard to the target cells used
(e.g., neoplastic T-cell lines, primary human lymphocytes, or genetically engineered cell lines), the method used to measure infection (e.g., p24
antigen, reverse transcriptase, cell killing, plaque formation, or reporter gene expression), the type of virus used (e.g., uncloned PBMC-derived
stocks, uncloned or molecularly cloned pseudoviruses, or replication-competent chimeric molecular clones), and whether single or multiple rounds
of infection are permitted. Note that Env-pseudotyped viruses produce a single round of target cell infection. The plasmid expression vectors used
to provide Env in trans can be clonal or can contain a quasispecies of env genes derived from a patient sample.
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termined with known reagents such as neutralizing monoclonal
antibodies and HIV-1-seropositive sera. This would provide
some assurance that the panel as a whole is not biased toward
a particular antibody repertoire. Additionally, there was agree-
ment that there are substantial advantages to the use of mo-
lecularly cloned viruses, such as Env pseudoviruses. Plasmid
env clones are stable, well-characterized reagents of known
sequence that can be readily transferred between laboratories.
The use of Env expression plasmids to produce Env-
pseudotyped viruses provides greater assurance that geneti-
cally similar virus stocks are generated each time, thereby
enhancing the accuracy and reproducibility of the assay. In
addition, molecularly cloned pseudoviruses enhance the scien-
tific value of the assay by permitting antibody specificities to be
mapped in relation to a precisely known Env sequence. Map-
ping the NAb response generated by different vaccines should
provide valuable information for future immunogen design.
Finally, once a panel of functional env plasmids is constructed,
less time and effort are needed to prepare pseudoviruses than
in the process of propagating uncloned viruses in donor
PBMC.
Several scientific questions were raised that need to be ad-
dressed to decide the most valid criteria for strain selection and
overall panel composition. This new information would pro-
vide guidance on how the initial panels may need to be mod-
ified. Key questions include the following. (i) Is antigenic drift
a concern that would require virus panels to change as the
epidemic progresses? (ii) How important is it to use recently
transmitted isolates rather than virus isolates obtained during
chronic infection? (iii) How do the neutralization properties of
clonal viruses compare to those of viral quasispecies in infected
individuals? (iv) Should env clones be derived from cultured
virus or directly cloned from plasma or PBMC of infected
individuals? (v) How do Env-pseudotyped viruses compare to
replication-competent virus with respect to Env incorporation
and neutralization phenotype? (vi) Do Env-pseudotyped vi-
ruses produced by transfection in nonlymphoid cells differ
from PBMC-derived viruses? (vii) What is the impact of using
genetically engineered cell lines as target cells? (viii) Finally,
what are the in vitro criteria for meaningful virus neutraliza-
tion, and can sera from recent phase III vaccine trials, where
protection was not observed, be used to establish such lower-
limit threshold values? Several of these issues are currently
being addressed, and there was a general consensus that these
scientific issues should be addressed concurrently with the im-
plementation of initial virus panels.
The number of virus isolates needed to compare vaccine
immunogens is another important issue. Based on the assump-
tion that breadth of neutralization is a key parameter of effec-
tive HIV-1 immunogenicity, the comparison of immunogens
would be based on the total number of viruses neutralized.
Statistical calculations can estimate the number of viruses and
vaccine sera that need to be tested in order to differentiate
immunogens. These sample size calculations depend on sev-
eral factors and assumptions that are beyond the scope of this
commentary, but the basic factors include the variability of
neutralization levels among vaccine recipients and the corre-
lation of neutralization levels among different isolates for the
same vaccine recipient (i.e., is each virus an independent mea-
surement, or are there relationships among viruses). As an
example, suppose we choose to compare two candidate vac-
cines against a panel of 12 viruses, a feasible number for testing
multiple immunogens. Depending on the statistical assump-
tions mentioned above, a study with between 20 and 40 vaccine
recipients per immunogen would have 90% power to distin-
guish an antibody response that neutralized 10% of viruses
from one that neutralized 30% of viruses. This type of statis-
tical analysis will facilitate vaccine comparisons and allow us to
discern incremental improvements that can be used to inform
future vaccine design.
This use of virus panels described here relates mainly to
preclinical and phase I/II testing of candidate vaccines. Addi-
tional issues arise when one considers phase III efficacy stud-
ies. For example, the vaccine sponsor and host countries may
want to know what percentage of regional viruses are neutral-
ized by the candidate vaccine being developed. Additional
efforts are planned to establish a valid panel size by testing
whether results obtained with an existing virus panel (e.g., of
12 strains from each genetic subtype) are predictive of results
obtained with a much larger number of strains matched in
genetic subtype to the standard panel. The results will play an
important role in shaping the size of standard virus panels used
in the future. Finally, critical information regarding immune
correlates of protection could be derived by careful measure-
ment of NAb responses during vaccine efficacy trials. The sci-
entific issues related to NAb measurements in phase III trials
are beyond the scope of this commentary, but the data derived
by testing vaccine candidates on standard virus panels will
likely play an important role in shaping the optimal measure-
ments to be made in future vaccine efficacy trials.
To facilitate a systematic approach to the evaluation of NAb
responses, we propose a three-tier algorithm for the evaluation
of novel immunogens (Fig. 2). Tier 1 would represent a triage
stage to identify immunogens that elicit a minimal level of
virus-neutralizing antibodies. Sera from vaccine recipients
would be tested against homologous virus strains represented
in the vaccine and a small number of heterologous viruses that
are known to be highly sensitive to antibody-mediated neutral-
ization. Examples of the latter viruses include the primary
isolate SF162 and T-cell-line-adapted viruses. This initial test-
ing would be of interest to those involved in the immunogen
design but would provide limited comparative data with other
immunogens. Testing in tiers 2 and 3 would provide a greater
measure of neutralization breadth for the purpose of compar-
ing immunogens. Tier 2 would utilize the virus panels de-
scribed above, i.e., panels of 12 viruses from each major ge-
netic subtype (A, B, C, D, E, and A/G), to test neutralizing
activity against viruses that are matched in genetic subtype to
the vaccine strain. As an example of tier 2 testing, an Env
immunogen based on a virus strain from clade C would be
tested against the clade C virus panel. This immunogen could
be compared to other immunogens designed to elicit clade C
NAbs. To assess breadth of neutralization against viruses from
other clades, a tier 3 virus panel would consist of a total of six
viruses from each of the heterotypic clades (i.e., in the case of
a clade C vaccine, tier 3 would include six viruses each from
clades A, B, D, E, and A/G). Tier 3 testing may also include an
additional set of viruses from the specific region of the world
where the vaccine is to be tested. Tier 3 testing would proceed
only if neutralization against tier 2 viruses was detected. Com-
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pletion of tier 2 and 3 testing would mean that serum samples
were assayed against at least 42 viruses, a number that should
be sufficient for characterization of neutralization magnitude
and breadth.
At the present time, only limited numbers of HIV-1 strains
that meet the criteria for selection as discussed above are
available as candidates for inclusion in standard panels. The
genetic and phenotypic characterization of an initial panel of
well-characterized molecularly cloned pseudoviruses for clade
B has been completed, and the corresponding Env expression
plasmids are now available through the NIH AIDS Research
and Reference Reagent Program (15). However, much more
work needs to be done before other panels can be assembled.
Although some progress is being made, a greater effort is
needed to acquire the desired isolates on a global scale and to
reduce these isolates to molecular clones for characterization
and eventual use. Until that time, existing non-clade B isolates
that only partially meet the criteria for panel composition
described above afford an immediate alternative. Examples
would be the well-characterized multiclade isolates from
chronically infected individuals recently described by Brown et
al. (2) and other isolates that may be obtained from the NIH
AIDS Research and Reference Reagent Program (www.aid-
sreagent.org).
In summary, we believe that the immunological assessment
of current and new HIV-1 immunogens should include testing
against standardized panels of pseudoviruses to allow compar-
isons of the potencies and breadths of elicited neutralizing
antibodies. These comparisons will facilitate the prioritization
of candidate vaccines in preclinical and clinical studies. Gen-
erating anti-HIV-1 neutralizing antibodies remains a major
scientific challenge for vaccine development, and the improved
assay accuracy associated with the use of standardized reagents
and clonal viruses should allow the measurement of incremen-
tal improvements in breadth and potency of neutralization that
might not otherwise be appreciated. While the virus panels
described here will be important for GLP assays, the Env
expression plasmids and related reagents needed to make
these pseudoviruses will be available to all investigators
through the NIH AIDS Research and Reference Reagent Pro-
gram. A top priority is to use these virus panels to assess the
NAb response generated in the recently completed phase III
trial of gp120 vaccine immunogens. This is the only antibody-
based vaccine candidate to be tested for efficacy in humans.
The results would establish a baseline level of neutralization
potency and breadth that is nonprotective, and this baseline
could be used to make informed decisions about advancing
future products.
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